Oxford BioMedica Announces Publication of Trovax® Phase III Analyses in Cancer Immunology, Immunotherapy
— Immune Response Surrogate Algorithm Shown to be a Significant Predictor of Clinical Benefit — Oxford, UK – 15 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”)…